Huntingtons Disease News From Medical News Today Latest Health News and Medical News posted throughout the day, every day.
Long-Term Efficacy Of Xenazine® (Tetrabenazine) For The Treatment Of Chorea Associated With Huntington's Disease
Lundbeck Inc. has announced the presentation of results from an open-label extension study of Xenazine® (tetrabenazine) for the treatment of chorea associated with Huntington's disease (HD)...
Protecting The Brain From A Deadly Genetic Disease
Huntington's disease (HD) is a cruel, hereditary condition that leads to severe physical and mental deterioration, psychiatric problems and eventually, death. Currently, there are no treatments to slow down or stop it. HD sufferers are born with the disease although they do not show symptoms until late in life...
Drug Shows Promise For Huntington's Disease
An early stage clinical trial of the experimental drug dimebon (latrepirdine) in people with Huntington's disease appears to be safe and may improve cognition. That is the conclusion of a study published in the Archives of Neurology...
Medication Appears Well Tolerated And May Have Beneficial Effects In Patients With Huntington's Disease
A medication previously studied in patients with Alzheimer's disease (latrepirdine) appears well tolerated and may improve thinking, learning and memory skills among individuals with Huntington's disease, according to a report in the February issue of Archives of Neurology, one of the JAMA/Archives journals...
Huntington's Disease: Discovery Of Mechanism In Brain Cell Injury Offers New Treatment Approaches
Scientists at the Brain Research Centre and Centre for Molecular Medicine and Therapeutics have uncovered a key cellular mechanism that alters brain cell function in Huntington's disease, and identified a possible treatment for the disease. The results of the study were published online today and will appear in the January 28 edition of the journal Neuron...
New Gene Involved In Autophagy, The Cellular Recycling Programme, Identified By Researchers
All cells are equipped with a recycling programme to collect and remove unnecessary cellular components. Autophagy sequesters and digests aged organelles, damaged proteins and other components, which, if not disintegrated and recycled, threaten cell viability...
Discovery Of Compounds That Help Protect Nerve Cells
Scientists at Duke University Medical Center have found some compounds that improve a cell's ability to properly "fold" proteins and could lead to promising drugs for degenerative nerve diseases, including Huntington's disease, Alzheimer's disease and Parkinson's disease. Misfolded proteins in nerve cells (neurons) are a common factor in all of these diseases...
Alnylam And Collaborators Present Data From Multiple Pre-Clinical And Clinical Programs At RNAi Keystone Symposium
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it presented data from multiple pre-clinical and clinical programs at the "RNA Silencing: Mechanism, Biology, and Application" Keystone Symposium held January 14-19, 2010 in Keystone, Colorado...
Evotec And CHDI Foundation, Inc. Extend Collaboration To Fight Huntington's Disease
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) announced the extension of its collaboration with CHDI Foundation, Inc. (CHDI) through to the end of 2012. The collaboration, which is aimed at finding new treatments for Huntington's disease and represents one of the largest joint innovation drug discovery CNS alliances within Evotec, will provide Evotec with up to US$ 37...
Elixir Announces First Sirtuin Inhibitor Clinical Trial
Elixir Pharmaceuticals, Inc. announced that its partner, Siena Biotech S.p.A., has commenced Phase 1 clinical testing of Elixir's potent, first-in-class SIRT1 (sirtuin-1) inhibitor for the treatment of Huntington's Disease...
Subtle Change Dramatically Reduces Pathogenic Potential Of Huntington's Protein
Scientists have identified a key molecular switch that may drive the onset of Huntington's disease (HD), an incurable neurodegenerative disorder that leads to severe disruptions in muscle coordination and cognitive function...
Huntington's Disease: IKK May Act As Both Inhibitor And Promoter
The kinase IKK phosphorylates the protein mutated in Huntington's disease to promote its removal and neuron survival, but IKK may be a double-edged sword that increases neurotoxicity in later stages of the disease. The study, led by researchers from the University of California, Irvine, was published online December 21 in the Journal of Cell Biology...
Amarin Neuroscience Ltd Withdraws Its Marketing Authorisation Application For Ethyl Eicosapent Soft Capsules (ethyl Eicosapent), Europe
The European Medicines Agency has been formally notified by Amarin Neuroscience Ltd of its decision to withdraw its application for a centralised marketing authorisation for the medicine Ethyl Eicosapent (ethyl eicosapent), 500 mg soft gelatine capsules...
Cedars-Sinai Regenerative Medicine Institute To Supply Stem Cells To Scientists Developing Treatments For Huntington's Disease
The Cedars-Sinai Regenerative Medicine Institute is to provide stem cells to a five-member National Institutes of Health consortium of researchers for development of potential therapies to treat Huntington's disease. As part of the $3.7 million grant from the National Institutes of Health, the Cedars-Sinai Regenerative Medicine Institute, directed by Clive Svendsen, Ph.D...
Researchers Find Potential Treatment For Huntington's Disease
Investigators at Burnham Institute for Medical Research (Burnham), the University of British Columbia's Centre for Molecular Medicine and Therapeutics and the University of California, San Diego have found that normal synaptic activity in nerve cells (the electrical activity in the brain that allows nerve cells to communicate with one another) protects the brain from the misfol...
Better Understanding Of Synaptic Activity May Support 'Use It Or Lose It' Hypothesis In Huntington's Disease
Investigators at Burnham Institute for Medical Research (Burnham), the University of British Columbia's Centre for Molecular Medicine and Therapeutics and the University of California, San Diego have found that normal synaptic activity in nerve cells (the electrical activity in the brain that allows nerve cells to communicate with one another) protects the brain from the misfol...
Efficacy Of Gene Therapy In Mouse Models Of Huntington's Disease Shown By Caltech Researchers
Researchers at the California Institute of Technology (Caltech) have shown that a highly specific intrabody (an antibody fragment that works against a target inside a cell) is capable of stalling the development of Huntington's disease in a variety of mouse models...
New TAU Formulation May Slow Down Parkinson's, Alzheimer's And Huntington's Diseases
Working like an architect, Prof. Hagit Eldar-Finkelman of Tel Aviv University's Sackler School of Medicine is "building" a new drug, L803-MTS, to treat a number of central nervous system (CNS) diseases like Alzheimer's. In pre-clinical studies, it also shows promise against Parkinson's, Huntington's and diabetes...
Gladstone And Partners Receive $3.7 Million For Huntington's Disease Research
The National Institutes of Health (NIH) has awarded a "Grand Opportunity" grant of $3.7 million to a consortium formed with the Gladstone Institute of Neurological Disease (GIND) and the Taube-Koret Center for Huntington's Disease Research to use stem cell technology to better understand Huntington's disease (HD) and to develop potential therapies...
Protein Inhibitor Helps Rid Brain Of Toxic Tau Protein
Inhibiting the protein Hsp70 rapidly reduces brain levels of tau, a protein associated with Alzheimer's disease when it builds up abnormally inside nerve cells affecting memory, neuroscientists at the University of South Florida found. The study is reported online today in the Journal of Neuroscience...
Mechanism For Potential Friedreich's Ataxia Drug Uncovered
Using clever chemistry, a Scripps Research team has pinpointed the enzyme target of a drug group that stops the progression of the devastating disease Friedreich's ataxia in mice and may do the same for humans...
What Is Huntington's Disease? What Causes Huntington's Disease?
Huntington's disease is an incurable, hereditary brain disorder. It is a devastating brain disorder for which there is no currently 'effective' treatment. Nerve cells become damaged, causing various parts of the brain to deteriorate...
Pfizer And Medivation Initiate Phase 3 Trial Of Dimebon In Patients With Huntington Disease
Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) announced the initiation of a Phase 3 trial of the investigational drug dimebon (latrepirdine) in patients with Huntington disease. The international safety and efficacy trial, known as HORIZON, is designed to evaluate the potential benefits of dimebon on cognition (thinking and memory) in patients with Huntington disease...
Disturbed Calcium Signaling May Play A Critical Role In Brain Cell Degeneration
University of Utah School of Medicine researchers and their colleagues at University of Texas (UT) Southwestern Medical Center have found strong evidence that abnormal calcium signaling in neurons may play an important role in the development of spinocerebellar ataxia type 2 (SCA2), a disorder causing progressive loss of coordination, speech difficulty, and abnormal eye movements...
In Huntington's Patients, Transplanted Neurons Develop Disease-Like Pathology
The results of a recent study published in PNAS question the long-term effects of transplanted cells in the brains of patients suffering from Huntington's disease. This study, conducted jointly by Dr. Francesca Cicchetti of Université Laval in Quebec, Canada, Dr. Thomas B...
Worlds Best Pharmacy
canadian meds shop
Why is your product so cheap? How do you ship orders? We accept : Visa, MasterCard, AmEx, Diners and JCB cards. |
